Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for the MagSense® HER2 breast cancer Phase I first-in-human study.
Read the announcement.
Home » First In-human Study Update: Study Open for Enrolment
Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for the MagSense® HER2 breast cancer Phase I first-in-human study.
Read the announcement.
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal
MELBOURNE and SAN DIEGO — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announced that the
https://youtu.be/LI18OcgM9XM Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems
We’re on a mission to make cancer more detectable.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance